Any current/future new fundraising through debt or equity?

No specific mention of any current or future fundraising through debt or equity in the transcript. The company discussed ongoing and upcoming capital expenditures, including INR 360 crores in FY24 and an expected INR 550 crores capex in FY25, mainly for capacity expansion and new product development. No direct statements about raising funds via debt or equity were provided during the call. The emphasis appeared to be on organic growth funded presumably through internal accruals or existing financial resources.

Any current/future capex/capital investment/strategic investment?

FY24 capex was about INR 360 crores, spread across Vinati Organics and its subsidiary VOPL. VOPL’s total capex approximately INR 500 crores, focused on anisole, MEHQ Guaiacol, 4’-Methoxyacetophenone, and isoamylene derivatives. One MEHQ Guaiacol plant commissioned in March; significant revenue expected from H2 FY25. Additional products in VOPL (anisole, 4-methoxyacetophenone, tertiary amyl alcohol, para tertiary amylphenol) also to be commissioned in H2 FY25. ATBS expansion delayed to Dec-Jan FY25 due to equipment delivery delays. FY25 overall capex guidance approximately INR 550 crores includ

Future growth expectations in sales/revenue/volumes?

Vinati Organics expects a revenue CAGR of approximately 20% over the next 3 years, driven by new products and existing portfolio growth. ATBS demand is recovering strongly, with expected robust double-digit growth in FY25. Butyl phenols business showed INR300 crores revenue last year, with growth expected in FY25 and capacity utilization nearing 100%. VOPL (Veeral Organics) is expected to double sales from INR130 crores to around INR280-300 crores in FY25. Peak revenue potential for VOPL is about INR500 crores, achievable in approximately 3 years. Antioxidant business revenue was around INR130

Future growth expectations in earnings/operating earnings/profits/EPS?

Vinati Organics expects strong double-digit growth in ATBS sales in FY25 following destocking normalization. For FY25, the company anticipates PAT to be 20-25% higher than FY24. EBITDA margins are expected to remain stable around 26%, supported by product mix including butyl phenols and antioxidants. Antioxidant business, currently at about INR130 crores, is expected to scale up significantly in FY25 and become a key growth driver. VOPL subsidiary revenues, which started in second half FY24 (~INR130 crores), are expected to nearly double to INR280-300 crores in FY25. Veeral Organics

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details on the current or expected order book or pending orders for Vinati Organics Limited. However, the company mentions strong demand recovery across products like ATBS, butyl phenols, and antioxidants. New product lines (e.g., at subsidiary VOPL) are in the commissioning phase with expected meaningful revenue contributions in the second half of FY25. Expansion projects (ATBS capacity expansion) are scheduled for completion in H2 FY25 to meet growing demand. The company expects double-digit growth in ATBS sales and increasing contributions from niche

Vinati Organics LtdQ4 FY24Chemicals & Petrochemicals

Vinati Organics Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,124P/E: 25.1Market Cap: ₹12.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Vinati Organics expects a revenue CAGR of approximately 20% over the next 3 years, driven by new products and existing portfolio growth.
ATBS demand is recovering strongly, with expected robust double-digit growth in FY25.
Butyl phenols business showed INR300 crores revenue last year, with growth expected in FY25 and capacity utilization nearing 100%.
VOPL (Veeral Organics) is expected to double sales from INR130 crores to around INR280-300 crores in FY25.
Peak revenue potential for VOPL is about INR500 crores, achievable in approximately 3 years.
Antioxidant business revenue was around INR130 crores in FY24, expected to scale up significantly in FY25 despite current weak demand.
Customized niche products and isoamylene derivatives in VOPL are upcoming growth areas with meaningful revenue from H2 FY25 onward.
Overall volume recovery is visible across key products post inventory destocking.

Margin guidance

Category 3

Vinati Organics expects strong double-digit growth in ATBS sales in FY25 following destocking normalization.
For FY25, the company anticipates PAT to be 20-25% higher than FY24.
EBITDA margins are expected to remain stable around 26%, supported by product mix including butyl phenols and antioxidants.
Antioxidant business, currently at about INR130 crores, is expected to scale up significantly in FY25 and become a key growth driver.
VOPL subsidiary revenues, which started in second half FY24 (~INR130 crores), are expected to nearly double to INR280-300 crores in FY25.
Veeral Organics (merged entity) sales are expected at around INR50 crores in FY25, with meaningful revenues mostly from FY26 onwards; peak revenue potential ~INR500 crores in 3 years.
Revenue CAGR target of ~20% over next 3 years driven by new and existing products.
Overall, profit and earnings growth are expected supported by volume recovery, product mix improvement, and new capacity ramp-up.

See what Vinati Organics Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No specific mention of any current or future fundraising through debt or equity in the transcript.
The company discussed ongoing and upcoming capital expenditures, including INR 360 crores in FY24 and an expected INR 550 crores capex in FY25, mainly for capacity expansion and new product development.
No direct statements about raising funds via debt or equity were provided during the call.
The emphasis appeared to be on organic growth funded presumably through internal accruals or existing financial resources.

Order book

The transcript does not provide explicit details on the current or expected order book or pending orders for Vinati Organics Limited.
However, the company mentions strong demand recovery across products like ATBS, butyl phenols, and antioxidants.
New product lines (e.g., at subsidiary VOPL) are in the commissioning phase with expected meaningful revenue contributions in the second half of FY25.
Expansion projects (ATBS capacity expansion) are scheduled for completion in H2 FY25 to meet growing demand.
The company expects double-digit growth in ATBS sales and increasing contributions from niche antioxidant products, suggesting a healthy demand pipeline.
The management emphasizes focusing on ROI and EBITDA over mere revenue, indicating a selective and quality-driven order intake process.
Overall, while specific order book numbers are not disclosed, the outlook signals robust order inflow and capacity utilizations nearing full levels for major products.

See what Vinati Organics Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

FY24 capex was about INR 360 crores, spread across Vinati Organics and its subsidiary VOPL.
VOPL’s total capex approximately INR 500 crores, focused on anisole, MEHQ Guaiacol, 4’-Methoxyacetophenone, and isoamylene derivatives.
One MEHQ Guaiacol plant commissioned in March; significant revenue expected from H2 FY25.
Additional products in VOPL (anisole, 4-methoxyacetophenone, tertiary amyl alcohol, para tertiary amylphenol) also to be commissioned in H2 FY25.
ATBS expansion delayed to Dec-Jan FY25 due to equipment delivery delays.
FY25 overall capex guidance approximately INR 550 crores including subsidiary investments.
33 MW solar power capacity commissioned to reduce emissions and conventional power dependence.

Track Vinati Organics Ltd — get its next earnings analysis in your feed

How does Vinati Organics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisVinati Organics Ltd

Rev 2Mar 3

See where Vinati Organics Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Vinati Organics Ltd rank in Chemicals & Petrochemicals?

Compare Vinati Organics Ltd against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Vinati Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Lords Chloro Alkali Ltd (Q1 FY27)
106.34 crore, a 6.88% YoY increase from Rs. Key investor presentation takeaways from Lords Chloro Alkali Ltd's Q1 FY27 investor presentation — and how it ranks
Prasol Chemicals Ltd (Q2 FY27)
Phase 1 Capex: INR 250 to 300 crores for expansion of existing products. Key concall takeaways from Prasol Chemicals Ltd's Q2 FY27 earnings call — and how it…
Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries vs Fine Organic Industries Ltd vs BASF India Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →